Arnuity® Ellipta® 薬物使用調査

基本情報

NCT ID

NCT03184480

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

336

治験依頼者名

GlaxoSmithKline

概要

The aim of this post-marketing investigation is to collect and assess the information about safety and effectiveness of ARNUITY® ELLIPTA® (hereinafter referred to as "Arnuity") in daily clinical practice. The investigation will include subjects with a diagnosis of asthma bronchial who are naïve to ARNUITY. The investigator will monitor the information about safety and effectiveness of ARNUITY for one year from the start date of ARNUITY administration and Pneumonia will be considered as the priority investigation matter. 300 subjects, from approximately 150 medical institutions, will be included in this analysis. ARNUITY ELLIPTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.

対象疾患

介入

依頼者（Sponsor）